TLC has a proprietary solution for pharmaceutical product development called NanoX®. NanoX® technology uses nanoparticles coated with the compound polyethylene glycol to reduce uptake by phagocytic cells of the immune system. This prolongs circulation in the body, allowing a drug to predominantly accumulate at particular disease sites such as tumors. Therapies based on NanoX® technology can also make use of additional molecular coatings to help nanoparticles to accumulate at cells of a specific type, such as tumor cells. |
Product |
Application Novel drug loading vesicles of small unilamellar liposomes (100nm±20nm) with an ionic gradient for active drug loading |
Advantages
|
TLC is looking for opportunities to collaborate with outside pharmaceutical companies by using our NanoX® product development solution. For information regarding licensing or research development opportunities, contact us.